Volitionrx (VNRX) Cash from Financing Activities (2011 - 2025)
Volitionrx's (VNRX) quarterly Cash from Financing Activities came in at $6.2 million in Q4 2025, up 168.83% YoY from $2.3 million in Q4 2024, and up 284.75% on a QoQ basis from $1.6 million in Q3 2025.
Volitionrx (VNRX) Cash from Financing Activities (2011 - 2025) Analysis & Trends
Volitionrx (VNRX) has 15 years of Cash from Financing Activities data on file, last reported at $6.2 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 168.83% year-over-year to $6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.1 million (up 97.44% YoY) and the FY2025 annual result came in at $17.1 million, up 97.44% from the prior year.
- Cash from Financing Activities rose to $6.2 million in Q4 2025, from $1.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $20.2 million in Q1 2021 to a low of -$460198.0 in Q2 2022.
- A 5-year average of $4.2 million and a median of $2.2 million in 2021 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 13203.23% in 2022, down 191.81% in 2022.
- Tracing VNRX's Cash from Financing Activities over 5 years: stood at $2.1 million in 2021, then plunged by 55.85% to $925964.0 in 2022, then jumped by 307.19% to $3.8 million in 2023, then plunged by 39.27% to $2.3 million in 2024, then surged by 168.83% to $6.2 million in 2025.
- The last three Cash from Financing Activities figures came in at $6.2 million (Q4 2025), $1.6 million (Q3 2025), and $5.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Volitionrx | 1.13 Mn | -1.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.16 Mn |
| Dec 31, 2025 | 6.16 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 5.67 Mn |
| Jun 30, 2025 | 5.67 Mn |
| Mar 31, 2025 | 3.67 Mn |
| Mar 31, 2025 | 3.67 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 5.60 Mn |
| Sep 30, 2024 | 5.60 Mn |
| Jun 30, 2024 | 973,435.00 |
| Jun 30, 2024 | 973,435.00 |
| Mar 31, 2024 | -209,398.00 |
| Mar 31, 2024 | -209,398.00 |
| Dec 31, 2023 | 3.77 Mn |
| Dec 31, 2023 | 3.77 Mn |
| Sep 30, 2023 | -274,758.00 |
| Sep 30, 2023 | -274,758.00 |